A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers
Latest Information Update: 26 Jul 2017
At a glance
- Drugs ARC 520 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Research Corporation
- 01 Aug 2017 Results published in the Clinical Pharmacology in Drug Development
- 09 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Oct 2014 Arrowhead escalated the dosage to 4 mg/kg, according to a media release.